Project Grant R43AR083327
Award Date
9/21/23
Completion Date
8/31/24
Dollars Obligated
$549K
Awardee
Knoubis Bio Inc. (REVESH5416V4)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $402,086 Project Grant (R01AR084689) to the University of Utah to develop joint-targeted antibody therapy for treating rheumatoid arthritis (RA). The grant, part of the NIAMS Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to localize therapeutic antibodies to arthritic joints by conjugating them to a collagen-hybridizing peptide (CHP) that binds to degraded collagen in...
This $1,288,152 Project Grant was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop a high-throughput screening method, named "JointSeq", to identify nanoparticles that can target specific cell types in the osteoarthritic joint. The overarching goal is to enable cell-specific delivery of therapeutics to treat...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $163,514 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Brigham & Women's Hospital Inc. The grant supports research to biochemically define a new G protein-coupled receptor (GPCR) signaling pathway with relevance to chemokine receptor signaling, particularly the CXCR3 receptor expressed on activated T cells. The project aims to discover how...
This federal Project Grant award of $220,224, awarded on July 4, 2024 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research by the University of Colorado to develop granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance bone tissue regeneration. The ultimate completion date for this project is...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $599,693 to The Hospital For Special Surgery Fund, Inc. for a 5-year period from August 1, 2024 to July 31, 2029. The research aims to elucidate molecular pathways and mechanisms that regulate myeloid cell function and osteoclastogenesis (bone-resorbing cell formation) under pathological...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $170,101 to Brigham & Women's Hospital Inc. to conduct research on spatial heterogeneity of synovial inflammation in rheumatoid arthritis (RA). The research aims to identify the spatial underpinnings of known RA subtypes and define new spatially-informed RA subtypes using advanced...
This $2,200,000 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award to Knoubis Bio Inc. in San Diego, CA will fund research and development of nonimmunosuppressive therapies for rheumatoid arthritis over a 2-year period from September 1, 2024 to August 31, 2026. The research aims to explore innovative approaches to the prevention, diagnosis, treatment, and management of this condition, with a...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $366,797 to the University of Missouri System to investigate the role of reverse transendothelial migration of neutrophils in the resolution of inflammation. The research aims to provide new knowledge and understanding of neutrophil trafficking during inflammation and the impact...
This $828,682 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) supports research to examine the timing and accuracy of rheumatoid arthritis (RA) diagnosis and their effects on outcomes for rural residents. The grant recipient, Mayo Clinic, a renowned non-profit academic medical center, will investigate challenges faced by rural populations in accessing timely RA diagnosis and...